You are here

Boehringer Ingelheim Pharmaceuticals, Inc.

Member Since 2013

Wolfgang Baiker

President and Chief Executive Officer

Dr. Wolfgang Baiker serves as President & CEO of Boehringer Ingelheim Pharmaceuticals, Inc. since March 01, 2018. He joined Boehringer Ingelheim in 1989 as Section Head for Clinical Development in Biberach, Germany. Since then, Dr. Baiker has served in a number of senior leadership roles across several critical business functions, including Head of International Project Management, Head of Global Development, Member of the Board of Managing Directors (BMD) responsible for Corporate Board Division Biopharmaceuticals and Operations and currently, as a key member of the worldwide Human Pharma Executive Committee. He serves as a Venture Partner of Wellington Ventures. Dr. Baiker has been a Member of the Board of Managing Directors of C.H. Boehringer Sohn AG & Co. KG and Boehringer Ingelheim GmbH since July 1, 2013. He works as the biopharmaceuticals and operations division, where he advises a fledgling company that was created in April 2014 as a spin-off from German research network the Life Science Inkubator. He served as a Senior Vice President of Development at Boehringer Ingelheim GmbH. He has been a Member of Advisory Board of NEUWAY Pharma GmbH since July 2014. Dr. Baiker also has significant experience working in the U.S. gained during a seven-year assignment in Ridgefield, CT where he held several different leadership roles within Clinical Development and Clinical Research. Dr. Baiker completed his medical studies and doctorate at the Universities of Bochum, Berlin, Ulm, Munich and Sheffield and received his MBA from Pace University in New York.

CEO Cancer Gold Standard™

Gold Standard  Employer

Gold Standard Employer Since 2013 | Gold Standard China Employer Since 2015

Quote

We are truly honored to receive this Gold Standard certification to acknowledge our company-wide efforts to make wellness an integral part of our culture and fight cancer in the workplace. In addition to our efforts at home, we are committed to bringing more health to the oncology community, from our research and development of innovative cancer treatments to resources and initiatives that provide education and support to patients, caregivers and healthcare professionals.

— Wolfgang Baiker

Gold Standard  Task Force Participation

Task Force Subcommittee: Ann E. Burke, Executive Director, Benefits

Task Force Member(s): Tanya Kory, Vice President and Business Unit Head, Oncology

Global Gold Standard  Task Force Participation

Member Global Gold Standard Subcommittee: Ann Burke, Executive Director, Benefits

Life Sciences Consortium

LSC  Task Force Participation

Task Force Member(s): Kevin Lokay, Vice President and Business Unit Head, Oncology

Further Support

Founding Member, CEO Roundtable on Cancer - China

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc. provides human prescription medicines. It offers pharmaceutical products for the treatment of lung health, cardiovascular diseases, men's prostate health, and anti-viral therapy. Its products include angiotensin II receptor blocker Micardis tablets for the reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes; and COMBIVENT RESPIMAT, an inhaler for patients with chronic obstructive pulmonary disease. The company’s products also include Flibanserin for the treatment of hypoactive sexual desire disorder in pre-menopausal women; SPIRIVA HandiHaler for the reduction of exacerbations in patients with chronic obstructive pulmonary disease; pramipexole dihydrochloride extended-release tablet for the signs and symptoms of early idiopathic Parkinson's disease; Pradaxa for the observational study on management of deep vein thrombosis and pulmonary embolism; and Viramune XR (nevirapine) extended-release tablets for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. In addition, its products include Tradjenta tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes; volasertib, an investigational inhibitor of polo-like kinase for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia; insulin glargine products for diabetic patients; nintedanib, an investigational therapy for the treatment of people with idiopathic pulmonary fibrosis; and Glyxambi tablets to improve glycemic control in adults with type 2 diabetes. It has a strategic partnership with Humana Inc. and a strategic collaboration with Sarah Cannon Research Institute. The company was founded in 1971 and is based in Ridgefield, Connecticut with research and development facilities in Ohio, Virginia, Germany, and Italy. The company operates as a subsidiary of Boehringer Ingelheim Corporation.